Viridian stock jumps on data for lead drug (NASDAQ:VRDN)
magicmine/iStock via Getty Images Viridian Therapeutics (NASDAQ:VRDN) on Tuesday announced topline results from its THRIVE Phase 3 clinical trial designed to assess its lead candidate veligrotug (VRDN-001) in patients with active thyroid eye disease (TED). Based on 15-week data, the company said that the 113-patient trial met the primary endpoint after five infusions, indicating a … Read more